Sutro Biopharma's (STRO) "Sell (E+)" Rating Reiterated at Weiss Ratings

Key Points

• Sutro Biopharma (NASDAQ: STRO) has had its "sell (e+)" rating reaffirmed by Weiss Ratings, signaling continued caution from analysts regarding its stock performance.
• Wells Fargo cut its target price on Sutro Biopharma from $4.00 to $3.00 while other firms have varied their ratings, with some analysts rating it as a "hold" or even upgrading to "overweight."
• Despite a reported revenue of $63.74 million for the last quarter, the company showed a significant negative net margin of 201.32% and is predicted to post a negative earnings per share of -2.92 for the current fiscal year.

Sutro Biopharma (NASDAQ:STRO - Get Free Report)'s stock had its "sell (e+)" rating reissued by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

STRO has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 12th. Wall Street Zen raised shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Finally, Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective on the stock in a research report on Monday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma has an average rating of "Hold" and an average target price of $4.47.

Sutro Biopharma Price Performance

NASDAQ:STRO opened at $0.85 on Wednesday. The firm's 50-day moving average price is $0.88 and its 200-day moving average price is $0.83. The company has a market capitalization of $72.37 million, a PE ratio of -0.34 and a beta of 1.61. Sutro Biopharma has a 1-year low of $0.52 and a 1-year high of $4.60.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.25. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. Equities analysts anticipate that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently made changes to their positions in STRO. RA Capital Management L.P. purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $2,885,000. Velan Capital Investment Management LP lifted its stake in shares of Sutro Biopharma by 197.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company's stock worth $2,185,000 after purchasing an additional 2,030,000 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Sutro Biopharma by 78.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company's stock worth $2,037,000 after purchasing an additional 1,382,661 shares during the period. AQR Capital Management LLC lifted its stake in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after purchasing an additional 1,206,330 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in shares of Sutro Biopharma in the 1st quarter worth approximately $490,000. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.